Study of JSKN016 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called JSKN016 for people with advanced cancer that has not responded to other treatments. It focuses on certain lung and breast cancers with specific genetic markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have advanced cancer that cannot be surgically removed or has spread, and it has not responded to or you cannot tolerate standard treatments.
- Your cancer type must be one of the following: AGA-positive non-small cell lung cancer (with specific gene changes like EGFR, ALK, or others) or HER2 IHC 0 breast cancer.
- You have at least one tumor that can be measured on scans, and you have not had prior treatment with certain antibody-drug combinations like DS-8201.
- You are in good enough health to walk and care for yourself (ECOG score 0 or 1) and your vital organs are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called JSKN027 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and if it can shrink tumors or slow their growth.
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
This trial tests a new drug, JSKN016HC, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
This trial tests a new drug called JSKN033 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug, JSKN033, in people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, and may be an option for those who have not improved with other treatments or have not yet had treatment.
Hear when a new Advanced Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.